FOR IMMEDIATE RELEASE

FRUITA, CO – September 2, 2026 – Neuralytix, LLC (www.nerve.health) today announced it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to assess the feasibility of a mechanomyography (MMG)-based system for quantitative nerve assessment during standard pain management procedures. The award (No. 1R43GM162022-01A1), officially titled "Mechanomyography-based system for quantitative nerve assessment during standard pain management procedures," provides approximately $353,000 over a one-year project period.

The program aims to establish the feasibility of adding objective, functional information to the anatomical picture clinicians rely on today, much as cardiac stress testing added functional data to coronary evaluation. According to the American Medical Association, back and neck pain are among the ailments that incur the highest amounts of total health care spending in the United States. Each year, doctors administer more than 10 million epidural steroid injections for back and neck pain, and because imaging can reveal multiple compressed nerve roots, physicians often face uncertainty about which nerves are contributing to a patient's pain. The Phase I work will prototype the system and evaluate the consistency and repeatability of its measurements in preclinical (bench and porcine) models. A subsequent Phase II would complete the testing required to pursue FDA 510(k) clearance.

"This award reflects the NIH's confidence that objective, functional information about nerve health is a question worth pursuing rigorously," said Christopher Wybo, Founder and CEO of Neuralytix. "We are grateful for NIGMS's support as we work to establish the feasibility of a quantitative approach that could one day help physicians make more informed decisions in the care of patients with nerve compression."

About Neuralytix, LLC

Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The company's iD3 System is FDA 510(k) cleared (K243636/K260992). The clinical application described in this NIH-funded research is a separate investigational program and is not cleared or approved for clinical use.

Research reported in this press release is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number 1R43GM162022-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FOR IMMEDIATE RELEASE

FRUITA, CO - August 6, 2026 - Neuralytix, LLC (www.nerve.health) today recognized Dr. Ross Jones, DO, an orthopaedic spine surgeon at Flagstaff Bone & Joint in Flagstaff, Arizona, as one of the first surgeons to adopt mechanomyography (MMG) as an intraoperative decompression endpoint, and as a foundational contributor to the growing peer-reviewed evidence base behind the approach.

Dr. Jones is a co-author of a 2025 pilot study in the Journal of Personalized Medicine, which followed 42 patients across 112 nerve decompressions and found that MMG threshold metrics anchored to a physiologic reference point were more predictive of post-operative pain relief than simple percentage-based threshold change (Abdulhak et al., 2025).

He is also lead author of a newly published 600-patient retrospective study in the North American Spine Society Journal comparing his own surgical outcomes before and after routinely adopting intraoperative MMG as a decompression endpoint (Jones & Nay, 2026). The study, which used a predicate MMG system prior to the iD3 System's commercial availability, found that 90-day unplanned return to the operating room fell from 9.7% to 2.7%, incidental durotomy fell from 9.7% to 2.3%, and mean 3-month pain scores improved from 4.91 to 1.93 on a 10-point scale. As a retrospective, single-surgeon analysis, the study's authors describe the findings as hypothesis-generating and call for prospective multicenter validation - but the magnitude and consistency of the association mark one of the most substantial single-surgeon adoption studies published on MMG to date.

"We can build the technology, but only surgeons can tell us whether it belongs in the OR." —  said Christopher Wybo, Founder and CEO of Neuralytix. "Dr. Jones has spent five years asking hard questions and testing them with data —  and the outcomes he's seeing are exactly the kind of signal that makes us optimistic about what MMG can mean for patients." 

About Neuralytix, LLC

Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The iD3 System is FDA 510(k) cleared (K243636/K260992). For more information, visit www.nerve.health.

FOR IMMEDIATE RELEASE

FRUITA, CO — August 5, 2026 — Neuralytix, LLC (www.nerve.health) today announced that Dr. Vikram Mehta, MD, MPH, FAANS, a board-certified neurosurgeon based in Newport Beach, California, is the first surgeon in the state to adopt its iD3 System, an FDA 510(k)-cleared mechanomyography (MMG) platform for intraoperative nerve assessment during spine surgery.

Dr. Mehta, who practices minimally invasive brain and spine surgery across several Orange County hospitals, has incorporated iD3 into two distinct parts of his practice. During lateral lumbar interbody fusion and other lateral approaches, he uses MMG to help confirm safe nerve-free access through the psoas corridor. During cervical and lumbar decompression procedures, he uses real-time MMG threshold measurements as an added data point to help inform his intraoperative judgment on decompression adequacy.

"Safe access and adequate decompression present two distinct challenges, and MMG gives me useful, objective information for each," Dr. Mehta said. "During lateral approaches, I want confirmation I'm not putting a nerve at risk before I ever place an instrument. During decompression, I want an objective signal alongside what I see and feel, in real time. Historically, surgeons haven't had an objective measure of decompression adequacy — we don't know how well we've done until the patient wakes up. Neuralytix helps us confirm, in the moment, that we've likely accomplished the goals of surgery, so patients are afforded the best possible chance of relief from nerve compression."

For patients seeking more information about Dr. Mehta's practice or to request a consultation, visit www.VikramMehtaMD.com

About Neuralytix, LLC

Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The iD3 System is FDA 510(k) cleared (K243636/K260992). For more information, visit www.nerve.health.

FOR IMMEDIATE RELEASE

FRUITA, CO — August 4, 2026 — Neuralytix, LLC (www.nerve.health) today announced full commercial availability of its iD3 System, an FDA 510(k)-cleared mechanomyography (MMG) platform that gives spine surgeons real-time, objective feedback on neurophysiologic changes occurring throughout decompression surgery. The launch builds on the system's initial commercial release in October 2025 and is now available through Neuralytix' U.S. distributor network.

The iD3 System is surgeon-directed and requires no dedicated technician or neurophysiologist — it integrates directly into existing surgical workflow. Using MMG, it measures how nerves are conducting and responding throughout decompression, giving surgeons a quantitative readout in an assessment that has traditionally relied on visual and anatomical judgment alone.

"At the end of every nerve decompression procedure, surgeons face the same question: is the nerve adequately decompressed?" said Christopher Wybo, Founder and CEO of Neuralytix. "Cardiology pairs the angiogram with the stress test because structure and function often diverge. With iD3, we're bringing that same functional stress test to spine surgery."

About Neuralytix, LLC

Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The iD3 System is FDA 510(k) cleared (K243636/K260992). For more information, visit www.nerve.health.